The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Market Value Trend Is Expected For The Bronchiolitis Obliterans Syndrome Market From 2026 To 2030?
The bronchiolitis obliterans syndrome market size has experienced significant expansion in recent years. It is anticipated to increase from $1.59 billion in 2025 to $1.73 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.1%. Historically, this growth can be ascribed to several factors, including the rise in organ transplantation, the occurrence of chronic graft rejection cases, enhanced hospital pulmonary care, the widespread use of immunosuppressants, and challenges related to limited early diagnostics.
The market for bronchiolitis obliterans syndrome is projected to experience substantial expansion over the upcoming years, with expectations to reach $2.43 billion by 2030 at a compound annual growth rate (CAGR) of 8.7%. This anticipated growth during the forecast period can be attributed to factors such as an increase in transplant procedures, advancements in early detection technologies, the emergence of personalized immunotherapy, the establishment of specialty respiratory centers, and improved long-term patient management strategies. Key trends expected within the forecast period encompass enhanced post-transplantation monitoring, the development and wider adoption of immunosuppressive therapies, the expansion of early diagnostic testing, a concentrated effort on preserving long-term lung function, and a growing need for specialized pulmonary care.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24488&type=smp
What Important Drivers Are Powering The Bronchiolitis Obliterans Syndrome Market Growth?
The increasing number of lung transplantations is projected to stimulate the growth of the bronchiolitis obliterans syndrome market. Lung transplantation is a surgical procedure where a healthy lung from a donor replaces a diseased or non-functional lung to improve a patient’s breathing. The rise in these transplantations stems from advancements in surgical techniques, which have substantially increased success rates and reduced complications, making the procedure safer and more accessible for those in need. For individuals with advanced bronchiolitis obliterans syndrome, lung transplantation effectively treats the condition by replacing damaged lungs with healthy donor lungs, thereby improving respiration and lung function. For instance, in January 2025, the Organ Procurement and Transplantation Network, a US-based non-profit scientific and educational organization, noted that lung transplants experienced their most significant proportional growth, increasing by 10.4 percent from 3,026 transplants in 2023 to 3,340 in 2024. This growing trend in lung transplants is therefore a primary driver for the expansion of the bronchiolitis obliterans syndrome market.
How Is Segment Classification Applied In The Bronchiolitis Obliterans Syndrome Market?
The bronchiolitis obliterans syndrome market covered in this report is segmented –
1) By Treatment Type: Medication, Oxygen Therapy, Lung Transplant
2) By Diagnosis: Pulmonary Function Tests, Imaging Tests, Lung Biopsy, Other Diagnosis
3) By Disease Type: Acute Bronchiolitis, Chronic Bronchiolitis Obliterans Syndrome
4) By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users
Subsegments:
1) By Medication: Immunosuppressants, Corticosteroids, Antibiotics, Bronchodilators, Anti-Inflammatory Agents
2) By Oxygen Therapy: Continuous Oxygen Therapy, Intermittent Oxygen Therapy, Portable Oxygen Therapy, Hyperbaric Oxygen Therapy
3) By Lung Transplant: Single Lung Transplant, Double Lung Transplant, Living Donor Lung Transplant, Retransplantation
What Trends Are Affecting The Growth Of The Bronchiolitis Obliterans Syndrome Market?
Major companies engaged in the bronchiolitis obliterans syndrome market are concentrating on creating advanced solutions, such as at-home nebulized therapy, to improve medication adherence and slow disease progression through targeted, continuous treatment. This at-home nebulized therapy involves using a nebulizer to transform liquid medication into a breathable mist, enabling direct delivery to the lungs. This convenient, self-administered treatment allows for effective management of respiratory conditions from the comfort of one’s home. For instance, in March 2023, Renovion, Inc., a US-based clinical-stage pharmaceutical company, launched ARINA-1, which obtained Food and Drug Administration (FDA) Fast Track Designation for its goal of preventing the progression of bronchiolitis obliterans syndrome (BOS) in patients with bilateral lung transplants. This regulatory milestone emphasizes ARINA-1’s potential to address a critical unmet medical need in transplant medicine. The Fast Track status facilitates more frequent communication with the FDA and prioritizes ARINA-1 for accelerated development and review, reflecting Renovion’s commitment to advancing respiratory health through innovative, patient-focused therapeutics.
Which Firms Are Competing In The Bronchiolitis Obliterans Syndrome Market?
Major companies operating in the bronchiolitis obliterans syndrome market are Novartis AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, AstraZeneca plc, Sanofi S.A., Johnson & Johnson (Janssen), AbbVie Inc., Bristol-Myers Squibb Company, Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Chiesi Farmaceutici S.p.A., Vertex Pharmaceuticals Incorporated, United Therapeutics Corporation, Insmed Incorporated, Viatris Inc., Zydus Lifesciences Ltd., Cadila Pharmaceuticals Ltd.
Access The Complete Bronchiolitis Obliterans Syndrome Market Report:
Which Regional Market Leads The Bronchiolitis Obliterans Syndrome Market?
North America was the largest region in the bronchiolitis obliterans syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bronchiolitis obliterans syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Bronchiolitis Obliterans Syndrome Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=24488&type=smp
Browse Through More Reports Similar to the Global Bronchiolitis Obliterans Syndrome Market 2026, By The Business Research Company
Bronchitis Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/bronchitis-treatment-global-market-report
Reversible Airway Diseases Treatment Market Report 2026
Tracheitis Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/tracheitis-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model